{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:50:09Z","timestamp":1790733009387,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xiamen Medical and Health Guidance Project, China","award":["No. 3502Z20224ZD1344"],"award-info":[{"award-number":["No. 3502Z20224ZD1344"]}]},{"name":"Xiamen Municipal Health High-Quality Development Science and Technology Program Project","award":["2024GZL-QN055"],"award-info":[{"award-number":["2024GZL-QN055"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12005-y","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:15:39Z","timestamp":1763021739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co\u2013 infection: a systematic review and meta\u2013 analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xianni","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruina","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siheng","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"1","key":"12005_CR1","first-page":"64","volume":"8","author":"BD Edwards","year":"2023","unstructured":"Edwards BD, Mah H, Sabur NF, Brode SK, et al. Hepatotoxicity and tuberculosis treatment outcomes in chronic liver disease. J Assoc Med Microbiol Infect Dis Can. 2023;8(1):64\u201374.","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"12005_CR2","doi-asserted-by":"crossref","unstructured":"Nader LA, Alves de Mattos A, Dornelles Picon P, et al. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor? Ann hepatol. 2010 Jan-Mar;9(1):70\u20134.","DOI":"10.1016\/S1665-2681(19)31682-5"},{"key":"12005_CR3","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12879-016-1344-2","volume":"16","author":"WS Kim","year":"2016","unstructured":"Kim WS, Lee SS. Lee,et.al.Hepatitis C and not hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50.","journal-title":"BMC Infect Dis"},{"key":"12005_CR4","unstructured":"Fern\u00e1ndez-Villar A et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2004."},{"key":"12005_CR5","unstructured":"Mohammed A, Agha et al. Prevalence of hepatitis C virus in patients with tuberculosis and its impact in the incidence of anti-tuberculosis drugs induced hepatotoxicity. Egypt J Chest Dis Tuberculosis. 2014."},{"issue":"4","key":"12005_CR6","first-page":"355","volume":"31","author":"Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association","year":"2023","unstructured":"Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association. Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version).Zhonghua Gan Zang Bing. Za Zhi. 2023;31(4):355\u201384.","journal-title":"Za Zhi"},{"issue":"12","key":"12005_CR7","doi-asserted-by":"publisher","first-page":"13751","DOI":"10.1111\/jvh.13751","volume":"29","author":"C Chou","year":"2022","unstructured":"Chou C, Veracruz N, Chitnis AS, Wong RJ. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: A systematic review and meta-analysis. J Viral Hepatitis. 2022;29(12):13751.","journal-title":"J Viral Hepatitis"},{"key":"12005_CR8","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1017\/S0950268820002861","volume":"148","author":"J Zheng","year":"2020","unstructured":"Zheng J, Guo MH, Peng HW, Cai XL, Wu YL, Peng XE. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies. Epidemiol Infect. 2020;148:e290.","journal-title":"Epidemiol Infect"},{"key":"12005_CR9","unstructured":"FDA Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009."},{"key":"12005_CR10","unstructured":"WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents. 2022."},{"issue":"7414","key":"12005_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"12005_CR12","doi-asserted-by":"crossref","unstructured":"Lee SS et al. Frequency and risk factors of drug-induced liver injury during treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 20(6):800\u20135.","DOI":"10.5588\/ijtld.15.0668"},{"key":"12005_CR13","doi-asserted-by":"crossref","unstructured":"Premashis, Kar et al. Clinical and molecular risk factors of anti-tubercular therapy induced hepatitis. J Clin Exp Hepatol. 2019 Mar-Apr;9(2):200\u20136.","DOI":"10.1016\/j.jceh.2018.06.012"},{"key":"12005_CR14","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Ungo JR, et al. Antituberculosis Drug\u2013induced hepatotoxicity the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871\u20136.","journal-title":"Am J Respir Crit Care Med"},{"key":"12005_CR15","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1378\/chest.06-2042","volume":"131","author":"YS Kwon","year":"2007","unstructured":"Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest. 2007;131:803\u20138.","journal-title":"Chest"},{"key":"12005_CR16","first-page":"616","volume":"14","author":"JY Chien","year":"2010","unstructured":"Chien JY, Huang RM, Wang JY, Ruan SY, Chien YJ, Yu CJ, et al. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2010;14:616\u201321.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12005_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jinf.2011.04.005","volume":"62","author":"JY Wang","year":"2011","unstructured":"Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, et al. Risk factors of hepatitis during Anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62:448\u201355.","journal-title":"J Infect"},{"key":"12005_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1086\/345906","volume":"36","author":"A Fernandez-Villar","year":"2003","unstructured":"Fernandez-Villar A, Sope\u2009~\u2009na B, Vazquez R, Ulloa F, Fluiters E, Mosteiro M, et al. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis. 2003;36:293\u20138.","journal-title":"Clin Infect Dis"},{"key":"12005_CR19","doi-asserted-by":"publisher","first-page":"934","DOI":"10.5588\/ijtld.12.0782","volume":"17","author":"CC Shu","year":"2013","unstructured":"Shu CC, Lee CH, Lee MC, Wang JY, Yu CJ, Lee LN. Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis. 2013;17:934\u20139.","journal-title":"Int J Tuberc Lung Dis"},{"key":"12005_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00408-013-9535-8","volume":"192","author":"YM Liu","year":"2014","unstructured":"Liu YM, Cheng YJ, Li YL, Liu CE, Hsu WH. Antituberculosis treatment and hepatotoxicity in patients with chronic viral hepatitis. Lung. 2014;192:205\u201310.","journal-title":"Lung"},{"key":"12005_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijmyco.2015.10.001","volume":"5","author":"E Samson","year":"2016","unstructured":"Samson E. Isa,et.al.Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos. Nigeria Int J Mycobacteriology. 2016;5:21\u20136.","journal-title":"Nigeria Int J Mycobacteriology"},{"issue":"11","key":"12005_CR22","first-page":"1069","volume":"47","author":"Chinese Medical Association Tuberculosis Branch","year":"2024","unstructured":"Chinese Medical Association Tuberculosis Branch. Guidelines for diagnosis and management of drug-induced liver injury caused by anti-tuberculosis drugs (2024 version).Zhonghua Jie he he Hu Xi. Za Zhi. 2024;47(11):1069\u201390.","journal-title":"Za Zhi"},{"issue":"1","key":"12005_CR23","first-page":"88","volume":"11","author":"Sakkarin","year":"2023","unstructured":"Sakkarin, Chirapongsathorn, et al. Characteristics of Drug-induced liver injury in chronic liver disease: results from the Thai association for the study of the liver (THASL) DILI Registry. J Clin Transl Hepatol. 2023;11(1):88\u201396.","journal-title":"J Clin Transl Hepatol"},{"key":"12005_CR24","doi-asserted-by":"crossref","unstructured":"Pengco, Cheny, Libz, et al. CausesClinicalfeatures and outcomes of drug- induced liver injury in hospitalized patients in a Chinese tertiary care hospital. SpringerPlus. 2015;(4):802.","DOI":"10.1186\/s40064-015-1600-8"},{"issue":"5","key":"12005_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3969\/j.issn.1672-3384.2023.05.007","volume":"21","author":"Z Chen Liujian","year":"2023","unstructured":"Chen Liujian Z, Jisheng Z, Jingsong, et al. Influence factors of Drug-Induced liver injury and mortality in patients with pulmonary tuberculosis and hepatitis B virus Co-infection. Chin J Clin Pharmacotherapy. 2023;21(5):33\u20138. https:\/\/doi.org\/10.3969\/j.issn.1672-3384.2023.05.007.","journal-title":"Chin J Clin Pharmacotherapy"},{"issue":"12","key":"12005_CR26","doi-asserted-by":"publisher","first-page":"e83892","DOI":"10.1371\/journal.pone.0083892","volume":"8","author":"N Lomtadze","year":"2013","unstructured":"Lomtadze N, Kupreishvili L, Salakaia A, Vashakidze S, Sharvadze L, Kempker RR, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS ONE. 2013;8(12):e83892.","journal-title":"PLoS ONE"},{"issue":"6 Pt 1","key":"12005_CR27","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1871\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"12005_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1440-1746.2012.07279.x","volume":"28","author":"H Devarbhavi","year":"2013","unstructured":"Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 2013;28(1):161\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"12005_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s15010-007-6125-9","volume":"35","author":"A Fernandez-Villar","year":"2007","unstructured":"Fernandez-Villar A, Sopena B, Garcia J, Gimena B, Ulloa F, Botana M, et al. Hepatitis C virus RNA in serum as a risk factor for Isoniazid hepatotoxicity. Infection. 2007;35(4):295\u20137.","journal-title":"Infection"},{"issue":"6","key":"12005_CR30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of","year":"2019","unstructured":"European Association for the Study of. The Liver. EASL clinical practice guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222\u201361.","journal-title":"J Hepatol"},{"key":"12005_CR31","unstructured":"Tien-En, Chang, et al. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis. J Chin Med Assoc Xx. 2017:1\u20138."},{"key":"12005_CR32","unstructured":"Tien-En, Chang, et al. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis. J Chin Med Assoc. 2017:1\u20138."},{"issue":"1","key":"12005_CR33","first-page":"945","volume":"29","author":"M Behzadifar","year":"2019","unstructured":"Behzadifar M, et al. Prevalence of hepatitis C virus in tuberculosis patients: A systematic review and Meta-Analysis. Ethiop J Health Sci. 2019;29(1):945\u201356.","journal-title":"Ethiop J Health Sci"},{"key":"12005_CR34","doi-asserted-by":"publisher","first-page":"101938","DOI":"10.1016\/j.eclinm.2023.101938","volume":"58","author":"ID Olaru","year":"2023","unstructured":"Olaru ID, et al. Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis. EClinicalMedicine. 2023;58:101938.","journal-title":"EClinicalMedicine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12005-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:15:42Z","timestamp":1763021742000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-12005-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12005"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12005-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study is a meta-analysis based on previously published data, and no individual patient data were collected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1566"}}